Characteristics of Long Covid: findings from a social media survey

Many people are not recovering for months after being infected with SARS-CoV-2. Long Covid has emerged as a major public health concern that needs defining, quantifying, and describing. We aimed to explore the initial and ongoing symptoms of Long Covid following SARS-CoV-2 infection and describe its impact on daily life in people who were not admitted to hospital during the first two weeks of the illness. We co-produced a survey with people living with Long Covid. We collected the data through an online survey using convenience non-probability sampling, with the survey posted both specifically on Long Covid support groups and generally on social media. The criteria for inclusion were adults with lab-confirmed (PCR or antibody) or suspected COVID-19 managed in the community (non-hospitalised) in the first two weeks of illness. We used agglomerative hierarchical clustering to identify specific symptom clusters, and their demographic and functional correlates. We analysed data from 2550 participants with a median duration of illness of 7.7 months (interquartile range (IQR) 7.4-8.0). The mean age was 46.5 years (standard deviation 11 years) with 82.8% females and 79.9% of participants based in the UK. 89.5% described their health as good, very good or excellent before COVID-19. The most common initial symptoms that persisted were exhaustion, chest pressure/tightness, shortness of breath and headache. Cough, fever, and chills were common initial symptoms that became less prevalent later in the illness, whereas cognitive dysfunction and palpitations became more prevalent later in the illness. 26.5% reported lab- confirmation of infection. The biggest difference in ongoing symptoms between those who reported testing positive and those who did not was loss of smell/taste. Ongoing symptoms affected at least 3 organ systems in 83.5% of participants. Most participants described fluctuating (57.7%) or relapsing symptoms (17.6%). Physical activity, stress and sleep disturbance commonly triggered symptoms. A third (32%) reported they were unable to live alone without any assistance at six weeks from start of illness. 16.9% reported being unable to work solely due to COVID-19 illness. 66.4% reported taking time off sick (median of 60 days, IQR 20, 129). 37.0% reported loss of income due to illness, and 64.4% said they were unable to perform usual activities/duties. Acute systems clustered broadly into two groups: a majority cluster (n=2235, 88%) with cardiopulmonary predominant symptoms, and a minority cluster (n=305, 12%) with multisystem symptoms. Similarly, ongoing symptoms broadly clustered in two groups; a majority cluster (n=2243, 88.8%) exhibiting mainly cardiopulmonary, cognitive symptoms and exhaustion, and a minority cluster (n=283, 11.2%) exhibited more multisystem symptoms. Belonging to the more severe multisystem cluster was associated with more severe functional impact, lower income, younger age, being female, worse baseline health, and inadequate rest in the first two weeks of the illness, with no major differences in the cluster patterns when restricting analysis to the lab-confirmed subgroup. This is an exploratory survey of Long Covid characteristics. Whilst it is important to acknowledge that it is a non-representative population sample, it highlights the heterogeneity of persistent symptoms, and the significant functional impact of prolonged illness following confirmed or suspected SARS- CoV-2 infection. To study prevalence, predictors and prognosis, research is needed in a representative population sample using standardised case definitions (to include those not lab- confirmed in the first pandemic wave). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 3

The morbidity burden of the COVID-19 pandemic is becoming increasingly apparent and concerning. Long Covid describes the condition of not recovering for many weeks or months following acute SARS- CoV-2 infection 1. It was first described and named as an umbrella term through a social media movement in Spring 2020 when many people with suspected or confirmed COVID-19 infection were not recovering weeks after onset of symptoms 2,3. Long Covid can occur regardless of the severity of the initial infection 4,5. The mechanisms underlying it are still largely unknown 6 and therefore it is premature to label all of its manifestations as a post viral illness3. Evidence describing the condition is scarce, but is starting to emerge on the long-term health impairment and organ damage following COVID-197–11. Patients are struggling to access adequate recognition, support, medical assessment and treatment for their condition, particularly those with no lab evidence of their infection during the first wave of the pandemic when testing was not accessible to those not hospitalised in the initial phase of their COVID-19 disease12,13. The prevalence of Long Covid is still uncertain, but evidence is emerging that it is relatively common. Data from the UK’s Office for National Statistics (ONS), based on a nationally representative non- institutionalised sample of lab-confirmed COVID-19 cases including asymptomatic ones, estimate a prevalence of 21% at 5 weeks, and 10% at 12 weeks from testing positive14. However, the detailed range of symptoms, disability, progression from the acute illness, and impact on work and daily activities are not well described in such non-hospitalised population-based surveys yet. For example, the ONS study based their estimates on a list of 12 symptoms included in the ONS infection survey15, with some of the common symptoms of Long Covid such as chest pain, palpitations and cognitive problems missing from that list. Other studies, some with a wider symptom list, estimate the prevalence of persisting symptoms to be higher at around one in three people for up to 18 weeks post infection4,5,16. There are more studies following-up hospitalised than non-hospitalised COVID-19 patients, with the assumption that hospitalisation indicates severe disease in most settings17–19. The natural history and pathology in those acutely severely ill with COVID-19 may be different to those developing Long Covid, but certain inflammatory or immunological mechanisms may be shared20. The multisystem nature of the illness is a common feature. A multi-country web-based survey of suspected and confirmed COVID-19 cases found a range of 205 symptoms, with respondents who had a duration of illness over 6 months experiencing an average of 14 symptoms10. A rapid living systematic review concluded that there is currently insufficient evidence to provide a precise definition of Long Covid symptoms and prevalence21. The National Institute of Health and Care Excellence (NICE) has defined “post-COVID-19 syndrome” as signs or symptoms that develop during or after acute COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis22. However, the ‘signs or symptoms’ that qualify for the definition are not specified. This may result in variation in diagnosis and referral among different clinicians, leading to inequalities in recognition and accessing services23. Many of those infected in spring 2020 did not have access to testing and therefore have struggled to receive recognition, diagnosis and support12,13. This study was conceived following conversations with people with Long Covid in the community who perceived a lack on data of COVID-19 sequelae in non-hospitalised individuals and felt a need for their experience to be explored and documented. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 4 In adults who self-reported suspected or confirmed COVID-19 and were not hospitalised in the first two weeks of their COVID-19 illness, we aimed to: • Characterise the initial and the ongoing symptoms of Long Covid in terms of their range, nature, pattern, progression and what triggers and relieves them • Describe the impact of Long Covid on daily activities and work

This is a cross-sectional online survey using a convenience non-probability sampling method. The survey was posted by the study authors on social media websites (Twitter and Facebook), including on the Facebook Long Covid Support Group (membership at the time of posting was around 30,000, the group was founded in the UK but has international membership too), and the smaller UK doctors #longcovid Facebook Group. Subsequently, it was shared on the Survivor Corps Facebook Group (USA), and the Body Politic Support Group on Slack (international) by members of these groups. These social media groups were selected for posting the survey because we aimed to recruit people who identify themselves as living with Long Covid as well those who believe they have recovered from the illness. CH is the founder of the Facebook Long Covid Support Group, and MEO is on the administrative team for that Group. They both have experience of Long Covid. The survey was available online in Microsoft Forms format, and open to complete for a period of one week, from November 7th to 14th 2020. The survey was only available in English, but responses were invited internationally, and not restricted to the UK, from those able to access the survey through social media and who fulfilled the inclusion criteria. The social media post contained brief information about the study, eligibility criteria and a link to the questionnaire. On opening the link, participants were taken to an in-depth participant information sheet. Participants gave their consent by answering ‘yes’ to a consent question. Participants had to consent to participating in the survey before they could access the questionnaire. Survey responses were anonymous, but participants who were willing to be contacted in the future for a follow-up survey were asked to consent to future contact and then provide contact details. Ethical approval for the study was granted by the University of Southampton, Faculty of Medicine Ethics Committee (Reference 61434). The survey data is available on request provided ethics committee approval for sharing the anonymised data is granted. Eligibility criteria The survey was restricted to adults aged 18 years or over who thought they had COVID-19 (confirmed or suspected) and who were not hospitalised for the treatment of COVID-19 in the first two weeks of experiencing COVID-19 symptoms. The screening questions for the survey were the following. • Are you aged 18 years or over? • Do you think you have had COVID-19? • Were you admitted to hospital in the first two weeks of experiencing COVID-19 symptoms? . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 5 If the participant answered ‘no’ to the first two questions or ‘yes’ to the third question, they could not progress further in the survey. Our survey provided an opportunity for people who were infected with SARS-CoV-2 but had not been hospitalised to participate in research to characterise their condition, since there were other studies following up hospitalised COVID-19 patients. In the UK, community testing for COVID-19 stopped on the 12th of March 202024, and was not available throughout Spring 2020. Most of those who experienced COVID-19 symptoms and did not require hospital admission during that period did not have a positive test result. Therefore, the survey was open to those who did not have lab confirmation of their infection, but they had suspected or clinically diagnosed COVID-19. The survey was also open to people who had fully recovered from confirmed or suspected acute COVID-19. Questionnaire components The questionnaire was co-produced working with public contributors experiencing Long Covid (CH and MEO). NAA also experienced Long Covid symptoms. Public contributor members of the COVID- 19 Research Involvement Group (a Facebook group founded by MEO for the purpose of encouraging patient involvement in COVID research) gave feedback on early versions of the questionnaire to ensure that the questions were appropriate and relevant. The survey was amended according to their feedback. The questionnaire included questions primarily about the individual respondents and focused on minimising participant burden by collecting data deemed essential. Questions included demographic information, baseline health, symptoms experienced at the start of COVID-19 illness, the pattern of illness over the course, symptoms that remained/appeared over the course of the illness, functional status, impact on health, activity, ability to work including current employment status, and healthcare usage. We collected data on pre-existing health conditions as a binary (yes/no) variable and used an open text response to collect details on these conditions. We also asked if other members of the household had experienced symptoms of COVID-19 and the duration of their illness. With the exception of questions on initial symptoms and functional status at six weeks of illness, all questions captured responses at the time of survey completion. The survey incorporated the Fatigue Severity Scale (FSS) to assess fatigue 25, and the Post-COVID-19 Functional Status (PCFS) Scale to assess functional status at six weeks from start of infection26. FSS consists of nine items scored on a seven-point Likert-type scale ranging from strongly disagree (1) to strongly agree (7). The nine items are combined into a total score calculated as the average of the individual item responses. A higher score indicates greater fatigue severity. We considered a score of 4 or above to indicate beyond normal levels of fatigue27. A PCFS scale variable was constructed consisting of grades 0-4 assigned based on yes/no responses to four component questions. Grade 0 reflects the absence of any functional limitation; grade 1 reflects the presence of symptoms, pain or anxiety without effect on activities (negligible functional limitations); grade 2 reflects the presence of symptoms, pain or anxiety requiring lower intensity of activities (slight functional limitations); grade 3 reflects the inability to perform certain activities (moderate functional limitations); and grade 4 reflects requiring assistance with activities of daily living (severe functional limitations). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 6 Statistical analysis Data were downloaded from Microsoft Forms once the survey was taken offline. Statistical analysis was undertaken using Stata 15.0 and R. R packages used included readstata13, mclust, stats, and ggplot2. A minimum duration of illness of four weeks was defined as Long Covid for the purposes of this analysis. Confirmed infection was defined as reported positive result of nucleic acid amplification test (NAAT) such as PCR, and/or antibody test. Descriptive percentages and summary statistics were generated for the full sample and stratified separately for those with lab-confirmed and suspected infection. Univariate comparisons between those with and without confirmed COVID- 19 infection were carried out using t-test for continuous variables and Chi square test for categorical variables. Complete case analysis was carried out as missing data was minimal. Questions on initial and ongoing symptoms were used to categorise symptoms as not experienced, initial only (experienced in the first two weeks of the illness), new symptom developed after the acute phase, and initial symptom that remained as an ongoing symptom. Brain fog, poor concentration, memory problems and confusion are presented as distinct symptoms but were also used to derive a combined variable for “cognitive dysfunction”. Similarly, chest pressure and chest tightness are distinct symptom questions used to derive a combined “chest pressure and/or tightness” variable. These derived variables were defined as having one or more of the component symptoms as initial and/or ongoing symptoms and categorised specifically for the derived variable. The percentages do not directly reflect the individual percentages of the component symptoms due to individuals having reported developing one (or more) component symptoms during different phases of the illness changing the distribution of the combined variable compared to the individual component symptoms. Ongoing symptoms were also categorised into the organ system affected (gastrointestinal, cardiopulmonary, neurological, systemic, nose/throat, pain and skin) (Supplementary Table 1). Clustering We examined symptom clusters based on acute symptoms reported to have been experienced in the first two weeks of the illness, as well as with reported ongoing symptoms. We carried out hierarchical agglomerative clustering using hclust implemented in the R package stats using the complete method of clustering. We first generated a dissimilarity matrix based on categorical binary data separately on symptoms during acute infection and with ongoing symptoms using Gowers distance. We used the silhouette method to identify the optimal number of clusters, by assessing both statistics for clusters 2 through 20. We examined the frequency of symptoms across different clusters in order to determine the clinical syndromes represented by the cluster. We examined patterns of transition of participants from acute clusters to ongoing clusters over time. We also examined demographic, socioeconomic, and functional correlates of the ongoing symptom clusters. Categorical variables were initially analysed using the Chi square test. Means for continuous variables were compared by regressing the variable on cluster number, using the lm() function in R, in univariate analysis. We then examined predictors of cluster membership by using multivariable logistic regression with cluster number as the dependent variable, and age, gender, ethnicity, income, education, alcohol consumption, smoking, baseline health, laboratory confirmation, acute symptom cluster membership, numbers of organ systems with at least one associated symptom, rest . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 7 in the first two weeks of the illness, and pre-existing conditions as predictors. In order to account for the impact of duration of illness, and time-specific effects, we also included the month of infection as indicator variable to allow for heterogeneity of effect, and the reported duration of illness as covariate. Age category was also included as an indicator variable rather than an ordinal variable to allow for heterogeneity of effect. As full analysis included those with and without lab-confirmed diagnosis of Long Covid, we examined whether this was a significant predictor of cluster membership to assess whether clusters correlated with having lab-confirmation of infection. We also carried out additional sensitivity analysis by clustering only those with lab confirmation to see if clusters obtained were different from full sample analysis.

A total of 2644 participants completed the survey; 94 with reported length of illness of less than four weeks (n=41) and those who had recovered from short acute COVID-19 (n=53) were excluded. The numbers of individuals who had recovered from short acute or Long Covid were too small to enable comparison. 2550 participants were included in this analysis, of which 675 participants (26.5%) reported that they had SARS-CoV-2 infection confirmed through PCR and/or antibody tests. The mean duration of illness was 7.2 months (standard deviation (SD) 1.8 months, median 7.7 months, interquartile range 7.4-8.0), with a mean duration of 6.2 months (SD 2.4) in those lab-confirmed compared to 7.6 months (SD 1.3) in those who were not. The mean age of participants was 46.5 years (SD 11 years). 82.8% were female and 93.3% were of White ethnicity. Responses were received from a range of places across the world, with the majority from the UK (79.9%: England 66.0%, Scotland 8.5%, Wales 4.5%, Northern Ireland 0.9%), North America (9.2%) and Europe (8.3%). In terms of educational attainment, 77.2% were qualified at university degree level or above (Table 1). Nineteen percent of participants reported that at least one other household member was also experiencing Long Covid (ill for 4 weeks or longer). Previous health A small proportion of participants reported poor (1.3%) or fair (9.2%) health prior to COVID-19 infection, with 89.6% reporting good, very good or excellent health before COVID-19. 47.3% reported having pre-existing health conditions with asthma, hypertension, and hyperthyroidism being the most common conditions reported (Supplementary Table 2). There were no significant differences in these proportions between those whose infection was lab-confirmed and those who were not (Table 1). Course of illness The most common initial symptoms (first two weeks of the illness) were exhaustion (75.9%), headache (65.5%), chest pressure and/or tightness (64.5%), shortness of breath (61.7%), cough (58.5%), muscle aches (55.2%), fever (51.1%) and chills (51.0%) (Table 2). In terms of ongoing symptoms, the most common were exhaustion (72.6%), cognitive dysfunction (brain fog, poor concentration, memory problems, confusion) (69.2%), chest pressure and/or tightness (52.6%), shortness of breath (54.2%), headache (46.0%), muscle aches (44.6%) and palpitations (42.0%) . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 8 (Table 3, Figure 1). Mean scores for each item on the Fatigue Severity Scale ranged between 5.2 and 6 (maximum (most severe) score is 7). Using a score of ≥4, the frequency of fatigue among survey participants was 86% (Table 3). Participants reported experiencing a mean of 12 (SD 6, median 11, IQR 7-16) initial symptoms and 10 (SD 6, median 9, IQR 5-14) ongoing symptoms. The most common initial symptoms that persisted past the acute phase were exhaustion (59.1%), shortness of breath (41.3%), chest pressure and/or tightness (40.5%), and headache (37.5%). At least one symptom of cognitive dysfunction was present in the initial first two weeks and persisted throughout the illness in 36.9% of participants but was also reported as new symptom(s) after the acute phase of the illness in 32.3% of participants, including brain fog (36.1%), memory problems (30.7%), and poor concentration (27.4%) (Supplementary Table 3). Ongoing symptoms affected three or more organ systems (gastrointestinal, cardiopulmonary, neurological, systemic, nose/throat, pain and skin) in 83.5% of participants, with 21.8% reporting symptoms that affected five systems, 15.0% six systems, and 4.7% seven systems (Table 3). The majority of participants reported a course of illness that was fluctuating (57.7%) or symptoms ‘coming and going’/relapsing (17.6%). 72.8% of participants experienced symptoms daily. Exhaustion improved on resting in 35.3% of participants. The majority of participants (60.4%) said that exertion (exercise/work) was not the only cause of exhaustion (Table 4). Only 2.3% of participants reported that they felt they had recovered to baseline health before COVID-19 with a further 20.1% reporting that they were not symptomatic at the time of completing the survey but did not feel they had recovered to pre-infection health and/or activity levels. The remaining 77.7% reported that they were experiencing symptoms at the time of completing the survey (Table 4). Of those who reported completely recovering from Long Covid (n=58), the duration of illness was 1-4 months for 65.5% and six months or longer for 13.8% (Supplementary Table 4). Common triggers that exacerbated existing symptoms or caused symptoms to return included physical activity (77.2%), stress (55.1%), disturbance in sleep patterns (46.9%), cognitive activity (42.2%), and domestic chores (35.0%). 23.2% reported symptoms varying by time of day. 15.8% of participants also reported not always being able to identify a trigger and sometimes symptoms returned or worsened without a trigger. Just over half of participants (54.3%) reported sufficient rest in the acute phase of the illness, with 26.0% reporting less rest than they would have liked due to caring or other responsibilities (Table 4). Functional ability At the time of completing the survey, being ill still affected respondents’ ability to carry out domestic chores (84.3%), leisure (84.8%) and social (77.1%) activities, work (74.9 %), self-care (50.0%), childcare (35.8%), and caring for other adults (26.1%), as well as affecting their mental health (63.7%). Using the PCFS Scale to describe how Long Covid affected daily activities at six weeks from the start of symptoms, nearly a third (32.3%) reported that they were unable to live alone without any assistance, and 34.5% reported moderate functional limitations (able to take care of self but not perform usual duties/activities). 89.5% of participants said they avoided certain activities/duties at six weeks from onset of illness. Only 10.3% reported no or negligible functional limitations (Table 5). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 9 Figure 1: Frequency of reported ongoing symptoms in survey participants (n=2526) Work At the time of responding to the survey, 9.7% reported working reduced hours, 19.1% reported being unable to work (out of which 88.3% was reported to be solely due to COVID-19 illness), and 1.9% reported being made redundant or having taken early retirement (Table 6, Figure 2). The most common reported reason for working reduced hours was COVID-19 illness (96.5%). 66.4% reported taking time off sick and 5.1% reported not needing to take time off sick as they were furloughed. The median time off sick was 60 (IQR 20 to 129) days. 37.6% reported a loss of income due to illness (median reported number of days for which income is lost 120, IQR 50 to 172). This was significantly higher for those with no lab confirmation (median 129, IQR 60 to 172) compared to those with lab confirmation (median 84, IQR 30 to 151). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 10 Healthcare utilisation Most participants reported at least one or more type of healthcare service usage (GP, 111 calls, Accident and Emergency, hospital outpatient appointments) with 12% admitted to hospital after 2 weeks from onset of illness. Figure 2: Reasons for change in work pattern in those reporting reduced work hours (n=243), being unable to work (n = 478) or being made redundant/taking early retirement (n-47) (total n= 768) Lab confirmation of infection Out of the 2550 participants, 675 (26.5%) reported lab confirmation of infection by either PCR or antibody test and 82 did not answer the question on testing for lab confirmation of infection (3.2%) (27.4% lab-confirmed out of n=2468 who answered the testing questions). 1582 participants (62%) reported having a PCR test with 426 testing positive (27% of those tested). The date of PCR test was available for 1491 of these 1582 participants. Twenty percent (n=304) were first tested at 0-5 days of onset of symptoms, with 72.7% of this group testing positive, while 80% (n=1187) were first tested ≥6 days of onset of symptoms, with 12.6% of this group testing positive. The date of antibody testing was available for 1120 of 1172 participants who reported having an antibody test, 26.3% (n=294) were first tested between 2 to 12 weeks of onset of symptoms and 42.1% of them tested positive, while 72.5% (n=812) were first tested ≥12 weeks from onset of symptoms with 27.7% testing positive 1172 participants (46%) reported having an antibody test with 369 testing positive (31% of those tested). 820 participants (32%) reported having both a PCR and antibody test of which 120 (15%) tested positive for both, 48 (6%) positive for PCR only and 122 (15%) positive for antibodies only. Overall, 5% (n=120) tested positive for both PCR and antibodies. Out of the 168 participants who tested positive for PCR and had an antibody test, 29% tested . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 11 negative for antibodies. Out of the 652 participants who tested negative for PCR and had an antibody test, 19% tested positive for antibodies (Supplementary Figure 1). Those with lab confirmation of infection were more likely to be working full-time (45.3%) at the time of responding to the survey than those who were not tested or tested negative (33.8%) (Table 6). Those will lab confirmation had similar patterns of illness and ongoing symptom frequency to those who tested negative or were not tested. The symptoms with the biggest difference between the two groups were loss/altered smell or taste (Table 3). Participants with lab-confirmed infection were more likely to report they had rested well in the first two weeks of the illness (60.4% vs 51.8%) (Table 4), more likely to have had time off sick (71.7% vs 64.3%), less likely to experience loss of income (33.3% vs 39.1%) (Table 6), and less likely to be unable to live alone at six weeks from onset (28% vs 33.8%) (Table 5). Clustering Thirty-four symptoms were used in clustering for acute symptoms (Table 2) and 35 for ongoing symptoms (Table 3). Clustering based on acute symptoms (initial symptoms experienced during the first two weeks) identified two clusters as the optimal number of clusters (Supplementary Figure 2). Acute symptom cluster (ASC) 1 consists of the majority of participants (88%, n= 2235) who exhibit predominantly cardiopulmonary symptoms, while ASC2 consists of the remaining 12% (n= 305) who exhibit multisystem symptoms (Supplementary Figure 3). On examining ongoing symptoms among ASCs 1 and 2, we found that although the differences between the groups persisted, they became less distinct primarily due to a large proportion of participants in ASC1 developing ongoing symptoms of cognitive dysfunction in addition to the predominantly cardiopulmonary symptoms over time. On clustering participants based on ongoing symptoms, we once again identified two optimal clusters (Figure 3), with ongoing symptom cluster (OSC) 1 predominantly including participants with cardiopulmonary symptoms, neuro-cognitive symptoms, and exhaustion (n=2243, 88.8%); and OSC2, a minority cluster, including multisystem ongoing symptoms (n=283, 11.2%). In univariate analysis, membership of OCS2 was associated with worse fatigue (FSS) and PCFS scores; needing to take time off sick; compromised ability to carry out self-care, domestic chores, care for other adults and childcare, work, participate in leisure, or social activities; greater risk of losing employment or needing to stop work (23% OSC2 vs 14% OSC1); and loss of income (52% OSC2 vs 36% OSC1). Membership of OSC2 was also associated with having a pre-existing condition, poorer baseline health, and greater healthcare usage with a higher number of GP consultations (6.1 OSC2 vs 4.7 OSC1) (Table 7). Multivariate fully adjusted analysis showed that being female (OR=2.0, 95% confidence interval (CI) 1.2, 3.4), poor baseline health (OR=3.4, 95% CI 1.2, 9.8), being a member of ACS2 (OR=2.5, 95% CI 1.7, 3.5), a higher number of acute symptoms related to different organ systems (OR=1.2, 95% CI 1.04, 1.31) were positively associated with membership of the more severe OCS2 cluster. Older age (>60 years) (OR=0.35, 95% CI 0.19, 0.66), higher income (OR=0.85 per increase in income category, 95% CI 0.75, 0.95), and sufficient rest in the first two weeks of the illness (OR=0.68, 95% CI 0.46, 0.99) seemed to be protective against OCS2. OSC2 membership was not related to the duration since onset of acute symptoms (Figure 4). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 12 In sensitivity analyses, we restricted to only participants who reported lab confirmation of infection. On hierarchical clustering into two clusters, consistent with our clustering on the whole dataset, we once again identified a majority cluster with cardiopulmonary, neurological symptoms, and exhaustion dominating (n=576), and a minority multisystem cluster where symptoms related to all systems were common (n=99) (Supplementary Figure 4). We found high correlation between ongoing clusters identified with the whole dataset, and those identified when limiting data to only those with lab confirmation (r=0.56, p<0.001). Figure 3: Two clusters of ongoing symptoms and acute symptoms among these clusters . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 13 Figure 4: Adjusted associations with developing multisystem ongoing symptom cluster (OSC) 2 Transition between clusters On examining the membership of acute symptom clusters by number of systems with at least one symptom, we found that 98% of those in ASC2 had 5 or more systems involved compared with 56% in ASC1. Even though acute symptom clustering strongly predicts ongoing symptom clusters, there is movement between clusters. Of those in OSC2, 73% had 5 or more systems involved compared with 59% in the OSC1. Both clusters had more multisystem involvement during the acute infection phase than the ongoing symptoms phase. Among 2223 participants clustering in ASC1, 9% (n=202) move into OSC2 over time, suggesting increase in severity. Among 305 participants in ASC2, 27% (n=81) remain in this cluster, with the remaining moving into OSC1, with cardiopulmonary, neurological, and fatigue symptoms predominating. Movement from ASC1 into OSC2 appears to be dependent on the number of organ system involvement, with those with more multisystem related symptoms more likely to move into the more severe cluster (Supplementary Figure 5). . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 14 Multivariate analysis suggested that gender and age were both predictors of transition from ASC1 to the more severe OSC2, with women being at higher risk (OR=1.8; 95% CI 1.1, 3.2), and participants aged >60 years at lower risk (OR=0.30, 95% CI 0.14-0.65). Number of systems with at least one associated symptom was also associated with higher likelihood of movement from ASC1 to OSC2 (OR=1.1, 95% CI 1.0, 1.3), while having a confirmed positive test (R=0.66, 95% CI 0.44, 0.99) and having rested well during the first two weeks of the illness were associated with lower likelihood of movement from ASC1 to OSC2 (OR=0.66, 95% CI 0.44, 0.99) (Supplementary Figure 6). Multivariate analysis was adjusted for duration of illness which was not associated with transition from ASC1 to OSC2. Month of infection was not included as a fixed effect in the analysis due to multi-collinearity with duration of illness.

Findings from this survey indicate that Long Covid is a debilitating multisystem illness for many of those experiencing it. Despite 9 in 10 of participants reporting good, very good, or excellent health before infection, a third said they were unable to live alone without assistance at six weeks from onset. At an average of 7 months into Long Covid, 50% of participants said their illness affected self- care, 64% said it affected their mental health, and 75% said it affected their work. The majority of participants reported a fluctuating or relapsing/remitting pattern of illness. Two-thirds had to take time off sick from work with over a third reporting loss of income due to their illness. The symptoms of exhaustion, cognitive dysfunction, shortness of breath, headache, chest pressure/tightness, and muscle aches predominated. 86% of participants had a score of 4 or above on the Fatigue Severity Scale. For most participants, several of their initial symptoms became less prevalent with time, with the stark exception of cognitive dysfunction and palpitations. However, for a minority of participants who had extensive multisystem involvement from the start, many symptoms tended to become more common with time.

This is a non-representative survey which recruited through online support groups as well as generally through social media. The survey sampling method was convenience non-probability sampling. This means that the sample was not randomly drawn from the population of interest to ensure representativeness, and therefore the findings cannot be generalised to the groups not represented among participants, nor can they be used in any way to calculate the prevalence of Long Covid. Respondents were predominantly White, female and of higher socioeconomic status. People living with Long Covid who use social media (and therefore were able to access the survey) could have different characteristics to those who do not use such platforms. Indeed, some of those with Long Covid in the community who are suffering ill health may not realise it is due to Long Covid, particularly if their infection was not lab-confirmed in the first place. In relation to the finding that the majority of participants being women, there is some evidence that Long Covid may be more common in women but not to the extent of the gender split seen in this survey 28. We tried to keep the survey as short as possible to be manageable, therefore some of the details around baseline characteristics, such as body mass index which requires self-measurement, were not collected. Although we asked about previous health status in general, we did not ascertain . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 15 the prevalence/absence of each reported symptom before COVID-19. Given the variable severity and disability levels among participants at the later stages of the illness, there is also the possibility of recall bias in this survey, as the data about the acute stage was collected retrospectively. The survey also aimed to collect data on those who have recovered from Long Covid and from short acute COVID-19 to allow comparisons of the acute symptoms between the two groups. However, the number of responses from these groups were too small to allow adequately powered comparisons. This likely reflects the motivation of individuals with Long Covid to participate in research which has Long Covid as its primary focus. Just over a quarter of survey participants reported having evidence of lab confirmation of COVID-19. However, the only pronounced differences in ongoing symptoms between those with lab confirmation and those without were the symptoms of loss/alteration of smell/taste. This is consistent with the other patient-led survey which included both confirmed and suspected cases of COVID-1910. This difference can potentially be explained by people who have these symptoms being more likely to seek testing due to being specific to COVID-19 and heavily advertised in public health campaigns, as in the UK, unlike many of the other common symptoms. Before loss of small/taste were added to the symptom lists, it could be that people experiencing them were more likely to seek healthcare input and hence get a test early on in their illness. It is important to note that people who reported testing negative were more likely to be tested much later in the illness than those who tested positive, again a consistent finding with Davis et al10. Also, the limitations of test accuracy and the importance of timing of testing (whether PCR or antibody) in relation to ascertaining SARS-CoV-2 infection are now well known29,30. Patient involvement A major strength of this survey is that it was co-produced with people with Long Covid (pwLC). The idea for the survey came from pwLC and they were involved in the research from the initial discussions to the writing of the manuscript. It was important for us to ask the questions that reflect the main areas of concerns expressed by pwLC. NAA experienced Long Covid Symptoms and has been a strong advocate of the recognition and measurement of the condition 31 32,33. MEO and CH, as well as experiencing Long Covid themselves, have a wide overview of the symptoms, disability, disease course and concerns as expressed in the support groups and other national forums given their extensive involvement in Long Covid advocacy. The survey questions also received wider input from the members of the COVID-19 Facebook Research Involvement Group and went through several rounds of reshaping based on all the feedback. We asked specific questions about the nature of the illness including triggers of symptoms, effect on work and daily activities, and also attempted to ascertain the acute symptoms pwLC experienced to explore how they are linked with ongoing symptoms. Although we list including suspected as well as lab-confirmed cases in the survey as a limitation, we also consider this a strength of the survey. Community testing in the UK was stopped in early March 2020 but became available to essential workers in May 2020, and community testing was restarted in late Spring/Summer 2020 24. It is vital that people who got infected in the first wave of the pandemic and unable to access testing during the acute phase of their illness are included in research. They represent a big proportion of people currently living with Long Covid, and have the . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 16 longest duration of illness, making it essential for studies about disease progression and prognosis to include them. We describe the differences and similarities between the groups (suspected and lab- confirmed) in the results section and the tables, as well as conduct sensitivity analyses of symptom clustering using the lab-confirmed subgroup only. However, we base our main findings on all survey participants. We argue that those experiencing acute COVID-19 symptoms at a time of high national prevalence of infection, and not recovered for months after their acute episode, are very likely to have been infected with SARS-CoV-2 even if their access to lab testing was delayed or not possible at the time. Main findings and comparison to other data Only 10% of survey participants reported less than good health prior to infection. The relapsing (comes and goes) or fluctuating nature of the illness was a prominent feature in most participants, but almost three quarters had daily symptoms. Many participants identified triggers for their symptoms, including physical or cognitive activity, stress, sleep disturbance and domestic chores. Avoiding the activities that trigger the symptoms mean adapting life routines accordingly. Some people may have life circumstances and job types that allow them to do that while others may not, leading to them feeling more unwell. This in turn has the potential to widen health and socioeconomic inequalities. Symptoms that were prevalent in the acute phase of the illness that were also common at the time of survey completion included exhaustion, breathlessness, headache, and chest pressure and/or tightness. We included separate questions about chest pain, chest pressure (heaviness) and chest tightness. Chest pain was also common both as an initial and ongoing symptom. Anxiety was reported by 28% and depression by 18% of participants. There are multiple reasons for anxiety in Long Covid including the unknown nature and prognosis of the illness, not having a definitive treatment, and the anxiety of not being believed by others including health professionals and employers. Alteration or loss of taste and smell were not among the most common ongoing symptoms in our survey, even in those with lab confirmation (21% and 24%), while sleep disturbance was experienced by 38% of participants. On clustering the ongoing symptoms, a minority cluster (OSC2: 11%) was detected with more multisystem involvement than the majority of participants (OSC1). In adjusted analysis, reporting sufficient rest during the first two weeks of the illness was associated with less likelihood of belonging to this cluster. It was also associated with less likelihood of moving from ASC1 to OSC2. Rest following acute infection is being recommended to prevent Long Covid 34. However, taking weeks to recuperate is not always a choice for people who have pressing work or caring responsibilities, or those who are unable to take adequate sick leave because of limited employment rights or financial difficulties. We stratified all of our main finding by test positivity. Most characteristics were similar between those who had lab confirmation and those who did not. A higher proportion of respondents who had a positive test reported that they rested well in the first two weeks of infection (60% vs 52%). This could be due to them recognising the seriousness of a COVID-19 illness having had a positive SARS- CoV-2 test and dedicating more time and resources towards their recovery and recuperation. This may in turn be linked to the finding that those who were lab-confirmed reported less functional . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 17 disability, and a lower proportion of them reported loss of income (33% vs 39%). However, a considerable proportion of them were still severely functionally affected with 28% unable to live alone without help, 59% unable to perform usual activities and duties, 87% avoiding certain activities or duties at 6 weeks, and 28% with severe functional limitations. Additionally, the duration of loss of income due to illness experienced was higher among those with no test confirmation. As the majority of respondents reported still being ill at the time of completing the survey, this is likely to increase. This may mean that those who had lab-confirmation had an advantage in terms of both clinical recognition and for employment rights. Descriptive findings from this survey on Long Covid are in line with findings from another online Long Covid survey which included participants from 56 countries with a majority from the United States10 . Both surveys found that Long Covid symptoms affect multiple organ systems, with fatigue and cognitive dysfunction identified as the most common persistent symptoms. However, Davis et al collected data on more symptoms and thus identified a higher number of organ system involvement. Common triggers for return or exacerbation of symptoms were physical activity, cognitive activity, and stress, though our survey also identified sleep disturbance as a common trigger. A recent study in Denmark (preprint) following up 198 non-hospitalised PCR positive COVID-19 patients at 4 weeks and 129 at 12 weeks found similar findings to ours with fatigue and cognitive symptoms being the most common. There were no major differences in the prevalence of symptoms at these two time points other than loss of smell/taste being less common at 12 than 4 weeks from onset. Women and people with higher body mass index were more likely to suffer from persistent illness 16. Another US study (preprint) of mainly non-hospitalised PCR positive cases (n=357) found a prevalence of symptoms of 36% after 30 days from onset and 15% at 90 days35. Although we asked about previous health status in general, we did not ascertain the prevalence/absence of each reported symptom before COVID-19 infection. A study in the Faroe Islands of 180 mainly non-hospitalised PCR positive patients found that 20% had three or more symptoms after an average follow up of around 4 months, with the most prevalent symptoms being fatigue, loss of smell and taste and joint pains. In this study, they had a much higher proportion of participants with ongoing symptoms compared to acute for most of the symptoms, including fatigue5. We provide a detailed assessment of the variation of symptoms across the course of the illness in Supplementary Table 3. Only 14% of our participants reported exhaustion as a new symptom not observed in the first two weeks of the illness, while 36% reported brain fog, 31% memory problems, and 27% poor concentration as symptoms they have not experienced in the first two weeks of the illness. It is possible that these symptoms were experienced in the first two weeks but because of the many other symptoms including fever, and people potentially being too ill to conduct cognitive tasks that require concentration, these were not specifically identified or recalled. A study which recruited confirmed and suspected COVID-19 cases from Facebook groups in the Netherlands and Belgium found the average number of symptoms among non-hospitalised patients was 14, compared to an average of 12 initial and 10 ongoing symptoms in our survey. The most prevalent were similar to what we found including fatigue, shortness of breath, headache, and chest tightness, however cognitive dysfunction symptoms were not ascertained as an item in their questionnaire. These symptoms were included as open-text though not analysed36. In another paper . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 18 from this study, it was reported that 52% of patients needed help with personal care more than two months from onset of symptoms, compared to before infection (8%)37. In our survey, 32% reported not being able to live alone without assistance at six weeks from onset of illness. At the time of completing the survey, a similar proportion (50%) said being ill affected their ability to self-care. Implications for research and practice Many questions remain unanswered and require further research. Particular issues building on the findings from this survey include further understanding disease progression and studying the longitudinal clustering of symptoms and organ pathology. This is important to inform prognosis and prediction of progression at an early stage of the illness, which will in turn inform intensity and timing of appropriate interventions. The question of what pharmacological and non-pharmacological treatments work to ‘cure’ Long Covid or to improve quality of life and prevent complications also requires urgent research. The impact of Long Covid on disadvantaged socioeconomic and ethnic minority groups needs to be quantified. Potential mechanisms explaining why certain age or demographic groups may be more at risk need to be explored. Equitable, inclusive and effective healthcare access is a fundamental right for all people living with Long Covid and must be systematically modelled to ensure services do not contribute to widening health disparities. Long Covid studies based on both surveys and clinical records are needed as they complement each other. There is an assumption that Long Covid studies based on recruitment from primary care, Long Covid clinics, or clinical records data are unbiased compared to community surveys. However, although this assumption may be justified for other more established medical conditions, it does not necessarily apply to Long Covid. Currently, healthcare access for Long Covid depends on many factors that may render healthcare research selective and unrepresentative. These include whether the person was tested or not, hospitalised or not, and their awareness that their own ill health may be linked to SARS-CoV-2 infection. This in turn, among other sociodemographic factors, will influence their health seeking behaviour. Also, clinicians’ own variation in diagnosis and cognitive biases in the absence of objective guidelines on case definitions can play a part in who gets a diagnosis and gets coded in the medical records as Long Covid. Therefore, future applied research needs to triangulate the findings from representative community-based surveys, healthcare studies and qualitative research of patients’ lived experiences. The prevalence of Long Covid remains uncertain and dependent on the case definitions used and the duration of follow up. However, we know at this stage that it is not uncommon, including those whose infection was considered ‘mild’. The number of cases will continue to increase if the virus continues to spread, therefore the issue of Long Covid and the impact it causes in terms of illness and disability is vital to pandemic and public health policy. This research demonstrates the impact of this prolonged illness on daily activities, work, physical, and mental health in a sample of predominantly healthy working-age individuals prior to infection. We explore how the acute symptoms are linked to the ongoing symptoms as a first step to help us characterise subgroups within the Long Covid umbrella. Long Covid is clearly a multisystem disease, and individuals experiencing it must be able to receive care from a co-ordinated multidisciplinary team. The current model of Long Covid clinics in the UK will only be successful if there are clear, inclusive, and equitable referral pathways and case definitions, and if effective and appropriately-resourced clinical input, investigations, treatments, and evidence-based rehabilitation become available. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 19

We thank all participants for their time and commitment completing this survey. We also sincerely thank members of the COVID-19 Research Involvement Group for providing feedback on earlier versions of the questionnaire. Author contributions Co-production of survey questions (NAA, NZ, CH, MEO, GY), survey design and administration (NAA, NZ), data management (NZ), statistical analysis (NZ, DG), manuscript first draft (NAA, NZ, DG), interpretation of results, input on draft, and approval of final version (all). Funding The study received no specific funding.

1. Nabavi N. Long covid: How to define it and how to manage it. BMJ. 2020;370. doi:10.1136/bmj.m3489 2. Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426. doi:10.1016/j.socscimed.2020.113426 3. Perego E, Callard F, Stras L, Melville-Jóhannesson B, Pope R, Alwan NA. Why the Patient-Made Term “Long Covid” is needed. Wellcome Open Res. 2020;5:224. doi:10.12688/wellcomeopenres.16307.1 4. Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med. Published online December 8, 2020. doi:10.7326/M20-5926 5. Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clinical Infectious Diseases. 2020;(ciaa1792). doi:10.1093/cid/ciaa1792 6. Altmann D, Boyton R. Confronting the pathophysiology of long covid. The BMJ. Published December 9, 2020. Accessed March 10, 2021. https://blogs.bmj.com/bmj/2020/12/09/confronting-the-pathophysiology-of-long-covid/ 7. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3557 8. Long-term Health Consequences of COVID-19 | Cardiology | JAMA | JAMA Network. Accessed October 22, 2020. https://jamanetwork.com/journals/jama/fullarticle/2771581/ 9. Dennis A, Wamil M, Kapur S, et al. Multi-organ impairment in low-risk individuals with long COVID. medRxiv. Published online October 16, 2020:2020.10.14.20212555. doi:10.1101/2020.10.14.20212555 . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 20 10. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. medRxiv. Published online December 27, 2020:2020.12.24.20248802. doi:10.1101/2020.12.24.20248802 11. Huang Y, Pinto MD, Borelli JL, et al. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic. medRxiv. Published online March 5, 2021:2021.03.03.21252086. doi:10.1101/2021.03.03.21252086 12. Ladds E, Rushforth A, Wieringa S, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Services Research. 2020;20(1):1144. doi:10.1186/s12913-020-06001-y 13. Kingstone T, Taylor AK, O’Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the “right” GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. Published online October 14, 2020. doi:10.3399/bjgpopen20X101143 14. Prevalence of long COVID symptoms and COVID-19 complications - Office for National Statistics. Accessed December 18, 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifee xpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications 15. Coronavirus (COVID-19) Infection Survey, UK Statistical bulletins - Office for National Statistics. Accessed December 18, 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsand diseases/bulletins/coronaviruscovid19infectionsurveypilot/previousReleases 16. Bliddal S, Banasik K, Pedersen OB, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. medRxiv. Published online January 25, 2021:2021.01.22.21249945. doi:10.1101/2021.01.22.21249945 17. Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603 18. Lu Y, Li X, Geng D, et al. Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI- based 3-month Follow-up Study. EClinicalMedicine. 2020;25. doi:10.1016/j.eclinm.2020.100484 19. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. European Respiratory Journal. Published online January 1, 2020. doi:10.1183/13993003.03276-2020 20. Bergamaschi L, Mescia F, Turner L, et al. Early immune pathology and persistent dysregulation characterise severe COVID-19. medRxiv. Published online January 15, 2021:2021.01.11.20248765. doi:10.1101/2021.01.11.20248765 21. Michelen M, Manoharan L, Elkheir N, et al. Characterising long-term covid-19: a rapid living systematic review. medRxiv. Published online December 9, 2020:2020.12.08.20246025. doi:10.1101/2020.12.08.20246025 22. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE. Accessed December 18, 2020. https://www.nice.org.uk/guidance/ng188 . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 21 23. Alwan N, Johnson L. Long COVID: where do we start with the case definitions? Published online December 21, 2020. doi:10.31219/osf.io/hndtm 24. Iacobucci G. Covid-19: Lack of capacity led to halting of community testing in March, admits deputy chief medical officer. BMJ. 2020;369:m1845. doi:10.1136/bmj.m1845 25. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. Archives of Neurology. 1989;46(10):1121-1123. doi:10.1001/archneur.1989.00520460115022 26. Klok FA, Boon GJ a. M, Barco S, et al. The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal. Published online January 1, 2020. doi:10.1183/13993003.01494-2020 27. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the Fatigue Severity Scale in a Swiss Cohort. Sleep. 2008;31(11):1601-1607. doi:10.1093/sleep/31.11.1601 28. Updated estimates of the prevalence of long COVID symptoms - Office for National Statistics. Accessed February 16, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifee xpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms 29. Ward H, Cooke G, Atchison C, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv. Published online October 27, 2020:2020.10.26.20219725. doi:10.1101/2020.10.26.20219725 30. Miller TE, Beltran WFG, Bard AZ, et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. The FASEB Journal. 2020;34(10):13877-13884. doi:10.1096/fj.202001700RR 31. Alwan NA. A negative COVID-19 test does not mean recovery. Nature. 2020;584(7820):170- 170. doi:10.1038/d41586-020-02335-z 32. Alwan NA. Nisreen Alwan: We must pay more attention to covid-19 morbidity in the second year of the pandemic. The BMJ. Published February 3, 2021. Accessed February 7, 2021. https://blogs.bmj.com/bmj/2021/02/03/nisreen-alwan-we-must-pay-more-attention-to-covid- 19-morbidity-in-the-second-year-of-the-pandemic/ 33. Alwan NA. Nisreen A Alwan: What exactly is mild covid-19? BMJ Opinion. Published July 28, 2020. Accessed August 12, 2020. https://blogs.bmj.com/bmj/2020/07/28/nisreen-a-alwan- what-exactly-is-mild-covid-19/ 34. Energy Envelope and prevention: Dr David Strain interview https://t.co/0Y9qn9NLeW. @ABrokenBattery. Published February 25, 2021. Accessed March 20, 2021. https://twitter.com/ABrokenBattery/status/1365066849692635138 35. Cirulli E, Barrett KMS, Riffle S, et al. Long-term COVID-19 symptoms in a large unselected population. medRxiv. Published online October 11, 2020:2020.10.07.20208702. doi:10.1101/2020.10.07.20208702 36. Goërtz YMJ, Herck MV, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV- 2 infection: the post-COVID-19 syndrome? ERJ Open Research. 2020;6(4). doi:10.1183/23120541.00542-2020 . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 22 37. Vaes AW, Machado FVC, Meys R, et al. Care Dependency in Non-Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2946. doi:10.3390/jcm9092946 Figure legends: Figure 1: Frequency of reported ongoing symptoms in survey participants (n=2526) Figure 2: Reasons for change in work pattern in those reporting reduced work hours (n=243), being unable to work (n = 478) or being made redundant/taking early retirement (n-47) (total n= 768) Figure 3: Two clusters of ongoing symptoms and acute symptoms among these clusters Figure 4: Adjusted associations with developing multisystem ongoing symptom cluster (OSC) 2 Supplementary Figure 1: Reported SARS-CoV-2 testing history in survey participants Supplementary Figure 2: Silhouette coefficient for 2 to 10 clusters Supplementary Figure 3: Two clusters of acute symptoms and ongoing symptoms among these clusters Supplementary Figure 4: Clustering of confirmed positive data only identifies similar clusters to whole dataset Supplementary Figure 5: Transition from acute symptom cluster to ongoing symptom clusters by number of systems affected by symptoms Supplementary Figure 6: Mutually adjusted predictors of transition from acute symptom cluster 1 (ASC1: cardiopulmonary predominant) to ongoing symptom cluster 2 (OSC2: multisystem) Table legends Table 1: Demographics and baseline health of survey participants Table 2: Initial symptoms experienced at the start of COVID-19 illness (first two weeks) Table 3: Ongoing symptoms, fatigue severity and organ systems affected Table 4: Duration, pattern and triggers of illness Table 5: Functional ability of study participants Table 6: Employment status and impact of illness on work Table 7: Correlates of Ongoing symptom clusters (n=2526) Supplementary Table 1: Classification of ongoing symptoms by organ system Supplementary Table 2: Pre-existing conditions in survey participants Supplementary Table 3: Symptoms categorised by phase of illness Supplementary Table 4: Duration and pattern of illness in those who reported full recovery from Long Covid . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 23 Table 1: Demographics and baseline health of survey participants Full sample Tested positive Tested negative or not tested p-value* n % n % n % Total n 2550 675 1793 Age, years (mean ± SD) (n= 2543) 46.5 ± 11.0 45.3 ± 10.9 46.6 ± 10.8 0.01 Age, categorised 18-30 189 7.4 68 10.1 118 6.6 0.006 31-45 997 38.2 271 40.2 712 39.8 46-60 1051 41.3 275 40.8 741 41.4 ≥60 306 12.0 60 8.9 217 12.1 Gender (n=2547) Male 413 16.2 101 15.0 290 16.2 0.22 Female 2108 82.8 572 84.7 1477 82.5 Non-binary 21 0.8 1 0.2 20 1.1 Prefer not to say 3 0.1 1 0.2 2 0.1 Other 2 0.1 - - 2 0.1 Country (n=2523) UK - England 1665 66.0 410 61.5 1203 67.5 <0.001 UK - Scotland 215 8.5 34 5.1 176 9.9 UK - Wales 114 4.5 23 3.4 85 4.8 UK - Northern Ireland 22 0.9 6 0.9 15 0.8 Outside the UK 507 20.1 194 29.1 302 17.0 Africa 18 0.7 16 2.4 2 0.1 Australia and New Zealand 15 0.6 7 1.0 8 0.4 Europe 210 8.3 60 9.0 145 8.1 South/Central America and Caribbean 10 0.4 5 0.7 5 0.3 North America 232 9.2 93 13.9 133 7.5 Asia 15 0.6 7 1.0 8 0.4 Middle East 7 0.3 6 0.9 1 0.1 Ethnicity (n=2533) White 2362 93.3 607 90.3 1688 94.4 <0.001 Mixed/Multiple ethnic backgrounds 67 2.7 18 2.7 47 2.6 Asian 64 2.5 25 3.7 36 2.0 Black/African/Caribbean 23 0.9 15 2.2 8 0.5 Other 14 0.6 7 1.0 7 0.4 Prefer not to say 3 0.1 - - 3 0.2 Educational attainment (n=2527) No formal qualifications 37 1.5 11 1.7 24 1.3 0.76 O levels or equivalent 209 8.3 57 8.6 145 8.1 A levels or equivalent 331 13.1 79 11.8 236 13.2 University degree or above 1950 77.2 520 78.0 1381 77.3 Smoking status (n=2537) Non-smoker 1577 62.2 424 62.9 1103 61.7 0.67 Ex-smoker 692 27.3 184 27.3 489 27.3 Current smoker 268 10.6 66 9.8 197 11.0 Alcohol intake in the 12 months before COVID-19 (n=2539) Do not drink 91 3.6 35 5.2 54 3.0 0.01 Did not drink in the past year 254 10.0 50 7.4 192 10.7 <Once a month 452 17.8 137 20.3 306 17.1 Once a month 210 8.3 62 9.2 144 8.0 Few times a month 514 20.2 135 20.0 368 20.6 1-3 times a week 708 27.9 186 27.6 498 27.8 4-6 times a week 245 9.7 55 8.2 182 10.2 Everyday 65 2.6 14 2.1 47 2.6 Baseline health before COVID-19 (n=2540) Poor 32 1.3 3 0.5 27 1.5 0.07 Fair 233 9.2 53 7.9 172 9.6 Good 675 26.6 199 29.5 462 25.8 Very good 1050 41.3 277 41.1 749 41.8 Excellent 550 21.7 142 21.1 382 21.3 Pre-existing health conditions (n=2541) No 1339 52.7 337 49.9 965 53.8 0.08 Yes 1202 47.3 338 50.1 828 46.2 *Comparisons between those with lab-confirmed COVID-19 and those who were not used t-test for continuous and chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 24 Table 2: Initial symptoms experienced at the start of COVID-19 illness (first two weeks) Full sample Tested positive Tested negative or not tested p-value* n % n % n % n 2540 675 1793 Fever 1298 51.1 362 53.6 893 49.8 0.09 Cough 1485 58.5 399 59.1 1037 57.8 0.57 Altered or loss of sense of smell 922 36.3 410 60.7 487 27.2 <0.001 Altered or loss of sense of taste 921 36.3 388 57.5 510 28.4 <0.001 Abdominal pain 562 22.1 150 22.2 402 22.4 0.92 Diarrhoea 855 33.7 235 34.8 601 33.5 0.54 Loss of appetite 946 37.2 293 43.4 624 34.8 <0.001 Nausea 642 25.3 176 26.1 451 25.2 0.64 Vomiting 148 5.8 47 7.0 99 5.5 0.17 Cognitive dysfunction 1168 46.0 315 46.7 822 45.8 0.72 Brain fog 797 31.4 226 33.5 550 30.7 0.18 Confusion 539 21.2 137 20.3 385 21.5 0.52 Memory problems 475 18.7 152 22.5 311 17.4 0.003 Poor concentration 730 28.7 198 29.3 516 28.8 0.79 Depression 187 7.4 57 8.4 126 7.0 0.23 Chest pain 991 39.0 239 35.4 728 40.6 0.02 Chest pressure 1314 51.7 323 47.9 967 53.9 0.007 Chest tightness 1379 54.3 338 50.1 1016 56.7 0.003 Palpitations 754 29.7 215 31.9 521 29.1 0.18 Shortness of breath 1566 61.7 405 60.0 1121 62.5 0.25 Chills 1296 51.0 359 53.2 910 50.8 0.28 Dizziness 1079 42.5 304 45.0 738 41.2 0.08 Exhaustion 1928 75.9 514 76.2 1367 76.2 0.96 Headache 1663 65.5 480 71.1 1138 63.5 <0.001 Hoarse voice 653 25.7 156 23.1 482 26.9 0.06 Nasal symptoms 717 28.2 231 34.2 466 26.0 <0.001 Sore throat 1161 45.7 291 43.1 837 46.7 0.11 Sneezing 242 9.5 85 12.6 148 8.3 0.001 Tinnitus 339 13.4 104 15.4 217 12.1 0.03 Joint pain 890 35.0 290 43.0 584 32.6 <0.001 Leg pain 573 22.6 179 26.5 370 20.6 0.002 Muscle aches 1402 55.2 425 63.0 936 52.2 <0.001 Pins and needles 388 15.3 109 16.2 263 14.7 0.36 Skin rash 289 11.4 81 12.0 198 11.0 0.50 Sleep disturbance 909 35.8 243 36.0 638 35.6 0.85 Number of initial symptoms, mean ± SD, median (interquartile range) 12 ± 6 11 (7 to 16) 13 ± 6 12 (8 to 17) 12 ± 6 11 (7 to 15) <0.001 *Comparisons between those with lab-confirmed COVID-19 and those who were not used t-test or Mann Whitney U for continuous and chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 25 Table 3: Ongoing symptoms, fatigue severity and organ systems affected Full sample Tested positive Tested negative or not tested p-value* n % n % n % n 2526 675 1792 Ongoing symptoms Fever 217 8.6 46 6.8 167 9.3 0.05 Cough 587 23.3 158 23.4 413 23.1 0.85 Altered or loss of sense of smell 358 14.2 165 24.4 183 10.2 <0.001 Altered or loss of sense of taste 313 12.4 141 20.9 164 9.2 <0.001 Abdominal pain 427 16.9 97 14.4 319 17.8 0.04 Diarrhoea 398 15.8 95 14.1 293 16.4 0.17 Loss of appetite 283 11.2 69 10.2 210 11.7 0.30 Nausea 412 16.3 90 13.3 315 17.6 0.01 Vomiting 46 1.8 9 1.3 37 2.1 0.23 Anxiety 715 28.3 213 31.6 493 27.5 0.05 Cognitive dysfunction 1747 69.2 480 71.1 1232 68.8 0.26 Brain fog 1490 59.0 427 63.3 1034 57.7 0.01 Confusion 520 20.6 145 21.5 363 20.3 0.50 Memory problems 1094 43.3 294 43.6 777 43.4 0.93 Poor concentration 1138 45.1 304 45.0 814 45.4 0.86 Depression 397 15.7 106 15.7 283 15.8 0.96 Chest pain 891 35.3 214 31.7 656 36.6 0.02 Chest pressure 970 38.4 263 39.0 695 38.8 0.94 Chest tightness 1023 40.5 247 36.6 752 42.0 0.02 Palpitations 1062 42.0 270 40.0 774 43.2 0.15 Shortness of breath 1370 54.2 370 54.8 977 54.5 0.90 Chills 373 14.8 77 11.4 286 16.0 0.004 Dizziness 980 38.8 256 37.9 703 39.2 0.55 Exhaustion 1834 72.6 494 73.2 1298 72.4 0.71 Headache 1161 46.0 320 47.4 827 46.2 0.56 Hoarse voice 453 17.9 103 15.3 342 19.1 0.03 Nasal symptoms 471 18.7 110 16.3 353 19.7 0.05 Sore throat 591 23.4 128 19.0 454 25.3 0.001 Sneezing 188 7.4 37 5.5 146 8.2 0.02 Tinnitus 662 26.2 159 23.6 477 26.6 0.12 Joint pain 950 37.6 252 37.3 681 38.0 0.76 Leg pain 668 26.4 184 27.3 472 26.3 0.65 Muscle aches 1126 44.6 303 44.9 795 44.4 0.82 Pins and needles 667 26.4 156 23.1 501 28.0 0.02 Skin rash 299 11.8 73 10.8 217 12.1 0.37 Sleep disturbance 952 37.7 241 35.7 691 38.6 0.19 Number of ongoing symptoms, mean ± SD, median (interquartile range) 10 ± 6 9 (5 to 14) 10 ± 6 9 (5 to 13) 10 ± 6 9 (5 to 14) 0.49 Fatigue Severity Scale score, mean ± SD (n=2000) 5.5 ± 1.4 5.5 ± 1.4 5.5 ± 1.4 0.38 Score ≥4 % 86 84 86 Number of organ systems affected 1 121 4.8 29 4.3 91 5.1 0.02 2 253 10.0 81 12.0 164 9.2 3 437 17.3 120 17.8 308 17.2 4 623 24.7 185 27.4 421 23.5 5 551 21.8 145 21.5 393 21.9 6 380 15.0 77 11.4 295 16.5 7 119 4.7 29 4.3 88 4.9 Organ systems affected by symptoms Gastrointestinal 909 36.0 220 32.6 666 37.2 0.04 Chest (cardiopulmonary) 2070 82.0 552 81.8 1471 82.1 0.86 Neurological 2164 85.7 582 86.2 1530 85.4 0.60 Systemic 2035 80.6 541 80.2 1445 80.6 0.79 Nose/Throat 1036 41.0 232 34.4 788 44.0 <0.001 Pain 1785 70.7 481 71.3 1261 70.4 0.67 Skin 299 11.8 73 10.8 217 12.1 0.37 *Comparisons used t-test or Mann Whitney U for continuous variables and chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 26 Table 4: Duration, pattern and triggers of illness Full sample Tested positive Tested negative or not tested p-value* Overall n % n % n % Total n 2550 675 1793 Well rested in first two weeks of illness (n=2536) No 437 17.2 98 14.5 326 18.2 0.002 Yes 1376 54.3 407 60.4 928 51.8 Less than I would have liked 658 26.0 154 22.9 489 27.3 Not sure 65 2.6 15 2.2 49 2.7 Back to baseline health (n=2538) No, still symptomatic 1971 77.7 531 78.7 1383 77.1 0.72 No, but not symptomatic 509 20.1 130 19.3 369 20.6 Yes 58 2.3 14 2.1 41 2.3 Duration of illness, weeks (mean ± SD) (n=2518) 31.3 ± 7.9 26.9 ± 10.6 33.0 ± 5.7 <0.001 Duration of illness, months (mean ± SD) 7.2 ± 1.8 6.2 ± 2.4 7.6 ± 1.3 <0.001 Pattern of illness (n=2519) Constant throughout 146 5.8 43 6.4 97 5.4 0.26 Gradually got worse 273 10.8 69 10.2 201 11.3 Gradually got better 201 8.0 63 9.3 130 7.3 Fluctuating 1454 57.7 394 58.5 1033 57.8 Comes and goes 394 15.6 96 14.2 284 15.9 Relapsing 51 2.0 9 1.3 41 2.3 Symptom frequency (n=2511) Daily 1827 72.8 485 72.2 1290 72.4 0.19 >3 times a week 425 16.9 126 18.8 295 16.6 Once a week 95 3.8 24 3.6 70 3.9 Once a fortnight 50 2.0 7 1.0 43 2.4 Once a month 32 1.3 6 0.9 26 1.5 <Once a month 20 0.8 9 1.3 11 0.6 Daily and reduced over time 21 0.8 6 0.9 15 0.8 Episodic 34 1.4 8 1.2 26 1.5 Variable 7 0.3 1 0.2 6 0.3 Triggers for return or exacerbation of symptoms (n=2474) Physical Activity 1911 77.2 500 75.8 1364 77.6 0.33 Diet 454 18.4 90 13.6 351 20.0 <0.001 Hormonal 582 23.5 138 20.9 438 24.9 0.04 Cognitive activity 1045 42.2 281 42.6 743 42.3 0.90 Work 705 28.5 206 31.2 485 27.6 0.08 Social activity 713 28.8 180 27.3 516 29.4 0.31 Stress 1364 55.1 332 50.3 994 56.6 0.006 Time of day 573 23.2 143 21.7 412 23.5 0.35 Sleep disturbance 1161 46.9 287 43.5 847 48.2 0.04 Domestic chores 866 35.0 213 32.3 632 36.0 0.09 Caring responsibilities 411 16.6 91 13.8 307 17.5 0.03 Unknown 404 15.8 123 18.2 275 15.3 0.08 Other - Talking 30 1.2 5 0.8 23 1.3 0.26 Other - Posture 18 0.7 2 0.3 15 0.8 0.15 Exhaustion improves on rest (n=2332) No 317 13.6 99 15.7 208 12.6 0.26 Yes 823 35.3 222 35.2 582 35.4 Sometimes 1192 51.1 310 49.1 855 52.0 Exhaustion caused by exertion (exercise/work) only (n=2343) No 1415 60.4 384 60.8 1006 60.8 0.96 Yes 241 10.3 62 9.8 174 10.5 Sometimes 506 21.6 135 21.4 352 21.3 Do not know 181 7.7 51 8.1 122 7.4 *Comparisons between those with lab-confirmed COVID-19 and those who were not used t-test for continuous and chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 27 Table 5: Functional ability of study participants Full sample Tested positive Tested negative or not tested p-value* n % n % n % Total n 2550 675 1793 Post-COVID-19 Functional Status Scale components at 6 weeks from start of symptoms Unable to live alone (n=2499) 808 32.3 187 28.0 599 33.8 0.006 Unable to perform activities/duties (n=2525) 1627 64.4 397 58.8 1191 66.4 <0.001 Suffer from symptoms, depression, pain or anxiety (n=2538) 2521 99.3 670 99.3 1782 99.4 0.73 Avoid activities/duties (n=2486) 2224 89.5 574 86.7 1602 90.4 0.008 Post-COVID-19 Functional Status Scale at 6 weeks from start of symptoms (n=2498) 0.01 No functional limitations 17 0.7 5 0.7 11 0.6 Negligible functional limitations 242 9.6 79 11.7 158 8.8 Slight functional limitations 588 23.3 178 26.4 403 22.5 Moderate functional limitations 871 34.5 226 33.5 622 34.7 Severe functional limitations 808 32.0 187 27.7 599 33.4 At the time of survey completion, being ill affected (n=2478): Self-care 1238 50.0 282 42.3 928 52.5 <0.001 Childcare 887 35.8 221 33.2 650 36.8 0.10 Caring for other adults 646 26.1 166 24.9 461 26.1 0.56 Domestic chores 2088 84.3 531 79.7 1517 85.8 <0.001 Work 1857 74.9 517 77.6 1324 74.9 0.16 Leisure activities 2101 84.8 537 80.6 1525 86.3 <0.001 Social activities 1911 77.1 491 73.7 1383 78.2 0.02 Mental health 1579 63.7 433 65.0 1122 63.5 0.48 *Comparisons between those with lab-confirmed COVID-19 and those who were not used chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 28 Table 6: Employment status and impact of illness on work Full sample Tested positive Tested negative/not tested p-value* n % n % n % Total n 2550 675 1793 Employment status at time of survey completion (n=2507) Working full-time 919 36.7 306 45.3 606 33.8 <0.001 Working part-time 340 13.6 72 10.7 265 14.8 Furloughed 58 2.3 9 1.3 47 2.6 Working reduced hours 243 9.7 65 9.6 176 9.8 Unemployed/Looking for work 45 1.8 9 1.3 36 2.0 Unpaid (Volunteer, Carer) 14 0.6 3 0.4 11 0.6 Student 61 2.4 20 3.0 41 2.3 Homemaker 101 4.0 16 2.4 79 4.4 Unable to work 478 19.1 133 19.7 342 19.1 Made redundant/took early retirement 47 1.9 6 0.9 39 2.2 Retired 155 6.2 27 4.0 115 6.4 Off sick 46 1.8 9 1.3 36 2.0 Lost job or had/chose to stop work (n=2483) No 1947 78.4 562 83.9 1362 76.4 <0.001 No but was furloughed 165 6.7 25 3.7 136 7.6 Yes 371 14.9 83 12.4 284 15.9 Had time off sick (n=2484) No 709 28.5 171 25.3 535 29.8 <0.001 No but was furloughed 126 5.1 20 3.0 105 5.9 Yes 1649 66.4 484 71.7 1153 64.3 Time off sick, days (median, IQR) (n=1564) 60 20 to 129 54 22 to 129 60 20 to 129 0.56 Loss of income due to COVID-19 illness (n=2479) No 1548 62.4 450 66.7 1092 60.9 0.008 Yes 931 37.6 225 33.3 701 39.1 Days income lost/too ill to work (median, IQR) (n= 622) 120 50 to 172 84 30 to 151 129 60 to 172 <0.001 *Comparisons between those with lab-confirmed COVID-19 and those who were not used t-test or Mann Whitney U for continuous and chi square test for categorical variables. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint 29 Table 7: Correlates of Ongoing symptom clusters (n=2526) Characteristic* Ongoing symptom cluster (OSC) 1 Ongoing symptom cluster (OSC) 2 p-value** Age (mean) 46.60 44.87 0.01 Gender (Male) 17 7 <0.001 Fatigue Severity Scale Score 5.36 6.30 <0.001 Post COVID-19 Functional Scale Score (PCFS) 2.82 3.29 <0.001 Duration of illness, days 219.73 221.29 0.65 Number of A&E visits 0.74 0.90 0.07 Number of GP consultations 4.71 6.10 <0.001 Number of hospital out-patient appointments 1.74 2.08 0.03 Number of days off sick 74.84 88.77 0.004 Number of days of income lost 109.97 136.88 <0.001 Pre-existing health conditions (Yes) 46 60 <0.001 Alcohol consumption in 12 months before COVID-19 infection <0.001 Do not drink 3 5 Did not drink in the past year 10 11 <Once a month 17 26 Once a month 8 9 Few times a month 20 22 1-3 times a week 29 20 4-6 times a week 10 7 Everyday 3 1 Self-reported health before COVID-19 infection <0.001 Poor 1 4 Fair 9 15 Good 26 33 Very good 42 35 Excellent 23 14 Being ill affected Self-care 47 75 <0.001 Childcare 34 43 0.002 Caring for other adults 24 42 <0.001 Domestic chores 83 97 <0.001 Work 74 84 <0.001 Leisure activities 84 94 <0.001 Social activities 75 91 <0.001 Mental health 62 79 <0.001 Hospitalisation for treatment of Long Covid symptoms <0.001 No 88 83 Ward – day stay 5 9 Ward – overnight stay 7 5 High dependency unit 0 2 Intensive care unit 0 0 Ambulatory care 0 0 Lost job or had/chose to stop work <0.001 No 80 69 No but was furloughed 6 8 Yes 14 23 Had time off sick <0.001 No 30 18 No but was furloughed 5 5 Yes 65 77 Loss of income due to COVID-19 illness <0.001 No 64 48 Yes 36 52 *Summary statistics are expressed as means for continuous variables and percentages for categorical variables. **Categorical variables were compared using the chi2 test and continuous variables were compared by regressing the variable on cluster number. . CC-BY-NC-ND 4.0 International licenseIt is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint The copyright holder for thisthis version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.21.21253968doi: medRxiv preprint